Targeting MUC4 in pancreatic cancer: miRNAs

Targeting MUC4 in pancreatic cancer: miRNAs.

MUC4 is a type I membrane-bound mucin expressed at the apical pole of normal polarized epithelial cells. MUC4 apomucin is characterized by a long hyperglycosylated extracellular domain, Epidermal Growth Factor (EGF)-like domains, a hydrophobic transmembrane domain, and a short cytoplasmic tail. MUC4 also contains NIDO, AMOP and vWF-D domains that are unique in the apomucin family. In cancers, M...

miRNAs in Pancreatic Cancer

Critical role of miRNAs in pancreatic cancer.

Pancreatic cancer (PC) is an aggressive malignancy with a high mortality rate and poor prognosis. Numerous investigations have shown that microRNA (miRNA) plays a vital role in PC. Thousands of miRNAs have been screened in PC and altered miRNAs, including circulating miRNAs, are associated with PC proliferation, apoptosis, metastasis, chemosensitivity, and radiosensitivity. Several studies have...

Diagnostic Utility of miRNAs in Cancer

Cancer is the one of most prevalent and leading causes of death in the world. Current ad­vancements in technology improve the understanding of the pathogenesis and pathology of cancers. But, due to enlarging mortality rates, poor prognosis, and lacunae in clinical early predictive biomarkers provide an important momentum to investigate novel early diagnos­tic/prognostic markers and spec...

Targeting eNOS in pancreatic cancer.

Mortality from pancreatic ductal adenocarcinoma cancer (PDAC) is among the highest of any cancer and frontline therapy has changed little in years. Activation of endothelial nitric oxide synthase (eNOS, NOS3, or NOS III) has been implicated recently in the pathogenesis of PDACs. In this study, we used genetically engineered mouse and human xenograft models to evaluate the consequences of target...